

Earnings Release

2Q21



About this report

Grupo Oncoclínicas presents its second quarter of 2021 results based on managerial analyses that the management believes best translate the Company's business, reconciled with international standards for Financial Statements (IFRS).



For further information, we recommend reading the Financial Statements of June 30, 2021, available on the Investor Relations website of the Grupo Oncoclínicas:

<https://ri.grupooncoclinicas.com/>

Content

| | | |
|---|---------------|----|
| 1 | THE GROUP | 4 |
| 2 | HIGHLIGHTS | 10 |
| 3 | NET REVENUES | 16 |
| 4 | EBITDA | 19 |
| 5 | NET INCOME | 22 |
| 6 | INDEBTEDNESS | 23 |
| 7 | CASH FLOW | 24 |
| 8 | RECENT EVENTS | 28 |



About Us

We are a leading company in the Brazilian private clinical oncology market that differentiates itself by our excellence in patient care.

We seek to lead the transformation of oncology treatment in Brazil by focusing on a comprehensive view of the patient, ensuring the best individualized and multidisciplinary treatment experience through an integrated oncology chain, from prevention, diagnostics and specialized treatments, all the way to continued care. Our mission to beat cancer is anchored on a patient-centered approach, putting the well-being and quality of life as the guide to our decisions in the short, medium, and long term.

Our goal is to become a world reference in cancer treatment and in oncological research, combining a qualified clinical staff with advanced therapies and technologies, as well as to raise the bar of oncological care in Brazil to the highest world standard, including international clinical protocols and cutting-edge technologies, and to contribute in a relevant way to international clinical trials, development of new therapies as well as increasing the survival rates of oncological patients in Brazil.

We started our activities in 2010, with a unit in the city of Belo Horizonte and have, ever since, gone through a national expansion process with the purpose of becoming a reference in oncology treatments in all regions in which we operate. Based on the solid relationships we have built with physicians and leading healthcare providers in each region, we have consolidated ourselves as a physician-driven organization, which enhances our ability to attract and retain a qualified multidisciplinary clinical staff.



Given our commitment to service quality and to putting our patients at the center of everything we do, we are always seeking to offer the best to our patients by leveraging on the strong, long-term relationships that we have developed with healthcare providers and the pharmaceutical industry, which includes offering the latest cutting-edge technologies and competitive, sustainable pricing terms for drugs and treatments.

We are the largest treatment provider in the private clinical oncology market in Brazil in terms of revenues, with 69 units, including clinics, genomics and pathology laboratories, and integrated cancer treatment centers, strategically located in 20 cities in Brazil. We also have an operation in the United States, where our bioinformatics activities are concentrated. In 2020, we performed more than 1 million consultations, through more than 1,000 dedicated specialist physicians with an emphasis in oncology. We are pioneers in the practice of precision medicine, the new frontier in cancer treatment and in the discovery of new drugs, through our genetic mapping tools and activities in the areas of pathology and bioinformatics. We operate high-tech laboratories that bring together genomics, pathological anatomy and clinical data processing, which allows us to provide our patients with accurate diagnostics and assertive, personalized treatment, with high rates of survival.



OC Precision Medicine

A New Frontier in Precision Medicine



One of the pillars of our DNA and our business model is to be at the innovative edge when it comes to precision oncology, with an emphasis on targeted therapies based on criteria such as genetic mapping of our patients. Mindful that the future of oncology lies on the development of precision oncology and in line with our culture of innovation, in 2019 we created a subsidiary fully dedicated to the practice of precision medicine, Oncoclinicas Precision Medicine ("OCPM"). OCPM offers a range of oncology products and services and has become a reference for both the medical community and the pharmaceutical industry in the search for the best therapeutic decisions and the development of targeted therapies. As an example, we perform differentiated molecular diagnostics, applying state-of-the-art genetic sequencing technology, tailored for the Brazilian reality and focused on supporting medical treatment decisions. Given the global nature of precision oncology and the absence of comparable companies in Brazil, the main reference companies in precision oncology, in addition to Oncoclinicas, would be Foundation Medicine (Roche) and Guardant Health and Flatiron (Roche).

As part of our precision oncology activities, we operate our own powerful bioinformatics structure, which was initially created from an acquisition in which we hold a majority stake - Boston Lighthouse Innovation ("BLI") - with Massachusetts General Hospital, affiliated with Harvard University. BLI is responsible for our bioinformatics tools for reading DNA and RNA while leveraging on artificial intelligence to interpret results, enabling adaptive genomic testing. In addition, we have established a team - our Oncology Data Science Team - dedicated to transforming our significant data lake into curated information that can be used for research-graded data and real world evidence. These data, anonymized and treated by our team of 120 dedicated collaborators in adherence to national and international data protection regulations, contribute to scientific research and assist our clinical staff in deciding the best treatments for our patients.

Also, in connection with our precision medicine practice, we have created a network of pathology laboratories with a full range of services, with a focus on interdisciplinary and collaborative work among our specialists in genomics, bioinformatics and oncogenetics. In April 2021, our pathology team became the first in the world to commercially use the first tool approved by the U.S. Food and Drug Administration (FDA), with breakthrough therapy status, for the use of artificial intelligence in decision support in pathological analysis in prostate cancer.

Finally, OCPM's differentiated performance also benefits from an international team of specialists, with internationally recognized members in management and scientific councils, ensuring access to the greatest opinion leaders in the market and, consequently, allowing OCPM to be at the innovative edge of the oncology market. We believe that OCPM's success is a reflection of our specialized oncology practice and is directly reflected in the quality of our services, in the attraction and retention of the best clinical staff in the industry, and in ensuring the long-term sustainability of our business, allowing us to explore new business models or strengthen business models that are part of our practice, such as participating in clinical trials and panels, providing databases for government agencies, the pharmaceutical industry, and other organizations that operate in the sector.

Oncoclínicas. Your life, our life.

It is from the plurality of its initiatives that
Oncoclínicas Group reinforces its mission of
Beat Cancer, with the purpose of taking care of our
patients' lives as if they were our own.




Oncoclínicas reaches record results

Operational Highlights

Robust and consistent growth in number of procedures and average ticket

- ✓ **93.2 thousand procedures** in the second quarter of 2021, an **increase of 27% compared to 2Q20**. In the half-year comparison, the increase was 20%;
- ✓ **Average ticket of R\$ 7.5 thousand** in 2Q21, representing a **6% increase over 2Q20**. In the half-year comparison, the increase was 10%;

Number of Procedures and Average Ticket



Making additional progress on our strategy of increasing ownership in existing units with proven performance track record

- ✓ **Acquisition of the totality of the capital in 5 units** in which we already had control: Recife (2 clinics), Belo Horizonte, João Pessoa and Aracaju;
- ✓ **Additional acquisition of interest in 4 companies** in Brasília (2 clinics), Curitiba and Vitória

Inorganic Growth: 3 Strategic Acquisitions in Progress

Acquisitions in Progress

CAM/Clion Group

On April 17, 2021 the Company, through its affiliate Núcleo de Oncologia da Bahia S.A. ("NOB"), entered into agreements for the purchase and sale of quotas for the acquisition of Grupo CAM/Clion. CAM Group is one of the most traditional medical organizations in Salvador and region, comprised of different multidisciplinary teams focused on comprehensive care of oncologic patients, distributed among 5 units in the cities of Salvador and Lauro de Freitas.

This acquisition will consolidate the Company's leadership position in Salvador, in addition to marking its entry into diagnostic medicine in connection with oncologic treatment.

The acquisition has been signed and is subject to approval by CADE.



Inorganic Growth: 3 Strategic Acquisitions in Progress (continued)

Acquisitions in Progress

CEBROM

On May 27, 2021, Oncoclínica - Centro de Tratamento Oncológico S.A., a subsidiary of the Company, entered into a purchase and sale agreement for the acquisition of (i) 100% of the capital stock of Centro Brasileiro de Radioterapia Oncologia e Mastologia CEBROM, (ii) up to 63.70% of the capital stock of CTR Centro de Tratamento Radioterápico, and (iii) up to 68.20% of the capital stock of CTR Centro de Tratamento Radioterápico de Anápolis.

CEBROM is the leader in oncologic assistance in Goiânia and region. Its activities are distributed across 3 units that have the most modern structure for integrated oncologic treatment, including radiotherapy technology.

The acquisition of CEBROM will mark the Company's entry into Goiás, its 12th state of operation, and the Federal District, one of the richest and fastest-growing regions in the country.

The acquisition has been signed and is subject to CADE's approval.



Inorganic Growth: 3 Strategic Acquisitions in Progress (continued)

Acquisitions in Progress


Complexo Hospitalar de Uberlândia S.A.

On July 6, 2021, Multihemo Serviços Médicos S.A., a subsidiary of the Company, entered into an agreement for purchase and sale of shares for the acquisition of 84% of the capital stock of Complexo Hospitalar Uberlândia S.A. ("UMC"), with an additional investment planned by the Company for the acquisition of two other companies (UMC Imagem and Instituto do Coração do Triângulo Mineiro).

UMC has the most modern hospital structure in the Triângulo Mineiro region, with 130 beds currently operational and an ongoing expansion for another 100 beds, expected to be ready this year.


The acquisition of UMC will consolidate the Company's presence in the Triângulo Mineiro region and enable the creation of a reference cancer center in Uberlândia, leveraging on the outpatient network that the Company already has in the region.

The acquisition has been signed and is subject to CADE's approval.



Footprint Expansion into Major Markets

Ongoing acquisitions strengthen Oncoclinicas presence in important markets and open new regional frontiers



Highlights of the 2nd Quarter 2021

Financial Highlights

Solid growth in net revenue (+32.6% 2Q21 vs. 2Q20) coupled with significant expansion in the Adjusted EBITDA margin (+220 bps), reaching 17.7% in 2Q21

- ✓ **Net revenue** totaled R\$ 640.2 million in 2Q21, an increase of 32.6% compared to 2Q20 and 4,2% compared to 1Q21, resulting mainly from the robust volume of treatments in the existing units (**73% of net revenue growth in 1H21 coming from organic operations**);
 - ✓ Growth of 34.1% in 1H21, reaching R\$1,254.8 million compared to R\$936.0 million in 1H20;
- ✓ **R\$ 189.5 million in gross profit in 2Q21**, an increase of 24.8% compared to the same period of the previous year;
 - ✓ In the semester, growth of 37.7% reaching R\$ 384.3 million compared to R\$ 279.0 million in 1H20, indicating gross margin expansion, which reached 30.6% in 1H21 against 29.8% in 1H20, growth of 80 bps;
- ✓ Adjusted Operating Expenses to Net Revenues in 2Q21 was 11.8% compared to 15.8% in 2Q20, representing a reduction of 400 bps in the periods observed;
- ✓ **Record Adjusted EBITDA of R\$113.3 million in 2Q21, 51.9% higher than in 2Q20;**
 - ✓ **In the semester, growth of 95.5%**, reaching R\$ 223.5 million compared to R\$ 114.3 million in 1H20, **with EBITDA margin reaching 17.8% in 1H21** against 12.2% in 1H20, **an expansion of 560 bps.**

Net Revenues

Robust and consistent growth of 33% in 2Q21 vs. 2Q20 and 34% in 1H21 vs. 1H20, of which approximately ¾ via organic


Net revenue in 2Q21 was R\$ 640.2 million, against R\$ 482.7 million in 2Q20, a growth of R\$ 157.6 million or 32.6%. This is the result of an increase in the volume of procedures of 27% combined with an increase in the average ticket of treatments provided of 6% in 2Q21 vs. 2Q20.

In the first half of 2021, net revenue totaled R\$ 1,254.8 million, 34.1% higher than the R\$ 936.0 million recorded in the same period of the previous year.

Of the 34.1% growth in net revenue in the first half versus the same period last year, 73% is attributed to organic growth and 27% to growth from M&A.

| (R\$ million) | 2Q21 | 2Q20 | Δ % | 1Q21 | Δ % | 1H21 | 1H20 | Δ % |
|---------------|-------|-------|-------|-------|-------|---------|---------|-------|
| Gross Revenue | 702.2 | 523.9 | 34.0% | 657.3 | 6.8% | 1,359.5 | 1,031.2 | 31.8% |
| Deductions | -62.0 | -41.2 | 50.5% | -42.8 | 44.9% | -104.7 | -95.1 | 10.1% |
| Net Revenue | 640.2 | 482.7 | 32.6% | 614.5 | 4.2% | 1,254.8 | 936.0 | 34.1% |

Net Revenue Growth (in R\$ million)



Costs


The total cost for the period was R\$450.7 million in Q2 2021, 36.2% higher compared to the R\$330.9 million cost in the same period last year. For the semester, total cost was R\$870.5 million, 32.5% higher than the R\$657.0 million in the previous year. In 1H21 the ratio of total costs to net revenue decreased 0.8 p.p. in relation to 1H20.

| (R\$ million) | 2Q21 | 2Q20 | Δ % | 1Q21 | Δ % | 1H21 | 1H20 | Δ % |
|-------------------------|--------|--------|-------|--------|------|---------|--------|-------|
| Net Revenue | 640.2 | 482.7 | 32.6% | 614.6 | 4.2% | 1,254.8 | 936.0 | 34.1% |
| Cost of goods sold | -450.7 | -330.9 | 36.2% | -419.8 | 7.4% | -870.5 | -657.0 | 32.5% |
| Cost over Net Revenue % | -70.4% | -68.5% | | -68.3% | | -69.4% | -70.2% | |

Gross Profit

Gross profit in the three-month period ended June 30, 2021 was R\$189.5 million compared to R\$151.8 million in the same period of 2020, which represented a positive variation of R\$37.7 million or 24.8% increase. Gross margin in 2Q21 was 29.6%, 2.1p.p. lower than the 31.5% in 2Q20 due to (i) 1.2p.p. lower provision for disallowances in 2Q20 compared to 2Q21 and (ii) 0.9p.p. due to the impact of recently inaugurated operations. In 1H21, gross profit amounted to R\$384.3 million compared to R\$279.0 million in the same period last year, with a gross margin of 30.6% against 29.8% in the previous year.

Gross Profit and Gross Margin (in R\$ million)



General and Administrative Expenses

The balance of general and administrative expenses in 2Q21 was R\$337.2 million versus R\$126.3 million in 2Q20. The increase in expenses was mainly due to the provision for the long-term incentive plan in the amount of R\$195.4 million.

Excluding the adjustments for extraordinary expenses and depreciation and amortization, the operating expense in the three-month period ended June 30, 2021 was R\$ 75.2 million compared to R\$ 76.1 million in the same period of 2020, a reduction of R\$ 843 thousand. The balance of operating expenses represented 11.8% and 15.8% of net revenue in the three-month periods ended June 30, 2021 and 2020, respectively.


In the first half of 2021, adjusted operating expenses totaled R\$ 158.3 million against R\$ 165.8 million in the previous year, a reduction of 4.6 p.p., reaching the level of 12.6% of net revenue in 1H21 compared to 17.7% in 1H20.

| (R\$ million) | 2Q21 | 2Q20 | Δ % | 1Q21 | Δ % | 1H21 | 1H20 | Δ % |
|--|---------------|---------------|---------------|---------------|---------------|----------------|---------------|--------------|
| Net Revenue | 640.2 | 482.7 | 32.6% | 614.6 | 4.2% | 1,254.8 | 936.0 | 34.1% |
| Adjusted Operating Expenses | -75.2 | -76.1 | -1.1% | -83.0 | -9.4% | -158.3 | -165.8 | -4.6% |
| Personnel and Third-Party Services | -71.7 | -68.5 | 4.5% | -64.5 | 11.1% | -136.2 | -135.4 | 0.6% |
| General and Administrative | -2.7 | -1.6 | 65.8% | -10.6 | -74.4% | -13.2 | -12.0 | 10.7% |
| Other operating income and expenses | -0.9 | -5.9 | -84.9% | -8.0 | -88.8% | -8.9 | -18.5 | -52.1% |
| Operating Expenses over Net Revenue % | -11.8% | -15.8% | | -13.5% | | -12.6% | -17.7% | |
| (+) Depreciation and Amortization | 36.0 | 23.8 | 51.5% | 27.9 | 29.2% | 63.9 | 47.0 | 36.0% |
| (+) Extraordinary items | 225.9 | 26.5 | | 28.5 | | 254.4 | 35.1 | |
| (+) EBITDA of newly opened operations | 10.1 | 2.6 | | 9.2 | | 19.3 | 4.5 | |
| (+) Long-term incentive plan expenses | 195.4 | 6.7 | | 8.4 | | 203.8 | 6.7 | |
| (+) M&A expenses | 6.3 | 0.7 | | 0.8 | | 7.1 | 3.0 | |
| (+) Pandemic of COVID-19 | 4.1 | 7.8 | | 2.3 | | 6.4 | 7.8 | |
| (+) Other extraordinary and/or non-operational | 0.6 | 2.2 | | 0.0 | | 0.6 | 2.2 | |
| (+) Precision Medicine | 9.4 | 6.6 | | 7.7 | | 17.1 | 11.0 | |
| Total Operating Expenses¹ | 337.2 | 126.3 | 167.0% | 139.4 | 141.9% | 476.5 | 247.9 | 92.2% |
| Total Operating Expenses on RL % | 52.7% | 26.2% | | 22.7% | | 38.0% | 26.5% | |

Adjusted EBITDA

Expansion of EBITDA Margin in the period, resulting from continued gains of scale in the platform and efficient expense management

Adjusted EBITDA in 2Q21 totaled R\$113.4 million, compared to R\$74.6 million in the same period of last year, an increase of 51.9%. In 1H21, Adjusted EBITDA was R\$223.5 million, 95.5% higher than the R\$114.3 million in the previous year. Adjusted EBITDA margin in 1H21 was 17.8% versus 12.2%, up 5.6p.p. due to (i) the Company's revenue growth and (ii) margin expansion supported by the decrease in adjusted operating expenses.



EBITDA (Cont)

| (In thousands of reais) | 2Q21 | 2Q20 | 1Q21 | 1H21 | 1H20 |
|---|------------------|----------------|----------------|------------------|-----------------|
| Net income/(loss) for the period/year | (202,527) | (3,653) | 6,593 | (195,935) | (24,045) |
| (+/-) Net financial income | 36,133 | 15,132 | 27,650 | 63,783 | 29,623 |
| (+) Current and deferred Income Tax/Social Contribution on Net Income | 18,738 | 14,022 | 21,149 | 39,888 | 25,520 |
| (+) Depreciation and amortization | 36,014 | 23,767 | 27,871 | 63,885 | 46,979 |
| EBITDA | (111,642) | 49,268 | 83,263 | (28,379) | 78,077 |
| (+) EBITDA of newly opened operations ¹ | 10,820 | 1,873 | 8,927 | 19,747 | 5,813 |
| (+) Long-term incentive plan expenses ² | 195,435 | 6,663 | 8,418 | 203,853 | 6,663 |
| (+) M&A expenses ³ | 6,303 | 700 | 843 | 7,146 | 3,041 |
| (+) Pandemic of COVID-19 ⁴ | 4,075 | 7,814 | 2,316 | 6,391 | 7,814 |
| (+) Other extraordinary and/or non-operational ⁵ | 550 | 2,163 | - | 550 | 2,163 |
| (+) Precision Medicine | 7,811 | 6,152 | 6,420 | 14,231 | 10,770 |
| Adjusted EBITDA | 113,352 | 74,634 | 110,186 | 223,538 | 114,342 |
| <i>EBITDA Margin</i> | <i>-17.4%</i> | <i>10.2%</i> | <i>13.6%</i> | <i>-2.3%</i> | <i>8.3%</i> |
| <i>Adjusted EBITDA Margin</i> | <i>17.7%</i> | <i>15.5%</i> | <i>17.9%</i> | <i>17.8%</i> | <i>12.2%</i> |

Adjusted EBITDA is a non-accounting measure prepared by the Company and corresponds to the EBITDA for the year or period, as the case may be, adjusted for extraordinary and/or non-operating items, including, but not limited to, (i) EBITDA of newly inaugurated operations, (ii) long-term incentive plan expenses, (iii) merger, acquisition and integration expenses, (iv) extraordinary expenses resulting from the COVID-19 pandemic and (v) other extraordinary and/or non-operating expenses. Adjusted EBITDA is not a measure recognized under Brazilian accounting practices or IFRS, does not have a standard meaning and may not be comparable to Adjusted EBITDA prepared by other companies. Adjusted EBITDA has limitations that may impair its use as a measure of profitability and should not be considered in isolation or as a substitute for net income, operating income or operating cash flow of the Company, a basis for dividend distributions or an indicator of liquidity, operating performance or payment capacity. The Company uses Adjusted EBITDA to measure its results without the influence of its capital structure, tax effects, other non-operating results and/or extraordinary items.

Financial income, net

The financial income, net, for the three-month period ended June 30, 2021 was negative by R\$ 36.1 million compared to negative R\$ 15.1 million in the same period of 2020, which represented a variation of R\$ 21.0 million or 138.8%. This increase is substantially attributed to the increase in the company's indebtedness in the period to finance acquisitions of new companies.

Income Tax

The income tax and social contribution balance for the three-month period ended June 30, 2021 was R\$18.7 million compared to R\$14.0 million for the same period in 2020, representing a change of R\$4.7 million or 33.6%. This increase is attributed to the increase in the pre-tax operating income of the operating units.



Net Income

The net accounting income in 2Q21 was a R\$ 202.5 million loss, compared to a R\$ 3.7 million loss in 2Q20. This impact is mainly due to the (i) Profit of newly opened operations (R\$ 16.7 millions), (ii) provision for the long-term incentive plan (R\$195.4 millions), (iii) M&A expenses (R\$ 6.3 millions), (iv) COVID-19 expenses (R\$ 4,1 millions), (v) other extraordinary and/or non-operational (R\$ 0,5 million) and (vi) Precision Medicine (R\$ 9,1 millions).

Net income attributable to non-controlling interests reduced from R\$9.1 million in 1Q21 to R\$2.4 million in 2Q21 due mainly to the increase in the controlling interest in the units.

Indebtedness


Indebtedness and Leverage Ratio

The Company's net debt at the end of Q2 2021 reached R\$ 978.7 million, representing a 70% growth compared to the amount reported at the end of 2020 when it had reached R\$ 576.8 million.




Financial leverage (measured through Net Financial Debt divided by Adjusted EBITDA for the last 12 months) increased from 1.8x in 2020 to 2.3x in the quarter.

Financial Leverage



Amortization Schedule (in R\$ million)



Cash Flow

Operating Cash Flow

The balance of cash consumed in operating activities before of the interest payments totaled R\$56 million for the first half of 2021, mainly due to (i) advance purchase of medicines of R\$57 million and (ii) the payment of extraordinary items.

Investment Cash Flow

The net cash balance generated in investing activities totaled R\$1.3 million for the first half of 2021, compared to the net cash balance consumed of R\$157.6 million for the same period in 2020. This variation is justified mainly by the acquisitions of property, plant and equipment and intangible assets of R\$109.2 million in 2020.

Financing Cash Flow

The net cash balance consumed in financing activities after the interest paid totaled R\$ 327.1 million for the 1H21 period, compared to R\$ 54.6 million generated in the 1H20 period. This variation is mainly explained by the amortization of loans in the semester, partnership, payment of acquisitions and purchase of minority interests.




Exhibit - Balance Sheet

| <u>ASSETS</u> | <u>06/30/2021</u> | <u>12/31/2020</u> |
|---|--------------------------|--------------------------|
| CURRENT | | |
| Cash and cash equivalents | 358,808 | 740,788 |
| Securities | 0 | 46,206 |
| Derivative financial instruments | 0 | 2,549 |
| Trade accounts receivable | 556,890 | 481,264 |
| Inventories | 52,818 | 37,461 |
| Recoverable taxes | 87,215 | 79,518 |
| Dividends receivable | 0 | 0 |
| Other Assets | 28,915 | 24,469 |
| Total current assets | <u>1,084,646</u> | <u>1,412,255</u> |
| NON-CURRENT | | |
| Securities | 34,818 | 32,795 |
| Escrow deposits | 11,112 | 10,986 |
| Deferred income tax and social contribution on net income | 40,660 | 31,415 |
| Related Parties | 27,892 | 18,630 |
| Advance for future capital increase | 0 | 0 |
| Other Assets | 68,763 | 48,176 |
| Investments in subsidiaries | 0 | 0 |
| Fixed Assets | 384,652 | 393,795 |
| Intangible assets | 1,257,397 | 1,208,647 |
| Right of use and leased assets | <u>204,496</u> | <u>220,620</u> |
| Total non-current assets | <u>2,029,790</u> | <u>1,965,064</u> |
| TOTAL ASSETS | <u>3,114,436</u> | <u>3,377,319</u> |

Exhibit - Balance Sheet

| LIABILITIES AND SHAREHOLDER'S EQUITY | 06/30/2021 | 12/31/2020 |
|---|-------------------------|-------------------------|
| CURRENT | | |
| Trade accounts payable | 308,386 | 345,686 |
| Loans and financing | 270,138 | 241,876 |
| Derivative Instruments | 14,466 | 0 |
| Social obligations | 69,190 | 63,746 |
| Tax liabilities | 80,709 | 84,571 |
| Income tax and social contribution payable | 24,374 | 22,732 |
| Accounts Payable for Acquisitions | 88,482 | 109,629 |
| Dividends payable | 17,487 | 18,526 |
| Leasing | 31,238 | 30,500 |
| Other Liabilities | <u>35,441</u> | <u>96,640</u> |
| Total current liabilities | <u>939,911</u> | <u>1,013,906</u> |
| NON-CURRENT | | |
| Loans and financing | 1,084,757 | 1,157,280 |
| Derivative Instruments | 2,971 | 0 |
| Social obligations | 344,764 | 140,911 |
| Tax liabilities | 3,745 | 3,977 |
| Deferred Taxes | 1,947 | 1,558 |
| Provisions for tax, labor and civil risks | 20,372 | 20,066 |
| Accounts Payable for Acquisitions | 237,299 | 95,675 |
| Related Parties | 0 | 6,411 |
| Advance for future capital increase | 9,380 | 8,476 |
| Leasing | 187,914 | 202,081 |
| Other Liabilities | <u>60,210</u> | <u>49,672</u> |
| Total non-current liabilities | <u>1,953,359</u> | <u>1,686,107</u> |
| SHAREHOLDER'S EQUITY | | |
| Paid-in share capital | 425,656 | 416,066 |
| Capital reserve | 466,746 | 466,746 |
| Equity valuation adjustment | 9,741 | 11,997 |
| Transaction between partners | -457,714 | -205,186 |
| Accumulated losses | -497,153 | -289,784 |
| Equity attributable to the participation of the parent company shareholders | -52,724 | 399,839 |
| Non-controlling Shareholders | <u>273,890</u> | <u>277,467</u> |
| Total shareholder's equity | <u>221,166</u> | <u>677,306</u> |
| TOTAL LIABILITIES & SHAREHOLDER'S EQUITY | <u>3,114,436</u> | <u>3,377,319</u> |

Statement of Income for the Year

| Statement of Income for the Year (in R\$ million) | 2Q21 | 2Q20 | Δ % | 1Q21 | Δ % | 1H21 | 1H20 | Δ % |
|--|---------------|---------------|---------------|---------------|---------------|----------------|---------------|----------------|
| NET REVENUE | 640.2 | 482.7 | 33% | 614.6 | 4% | 1,254.8 | 936.0 | 34% |
| Cost of Goods Sold | -450.7 | -330.9 | 36% | -419.8 | 7% | -870.5 | -657.0 | 33% |
| GROSS PROFIT | 189.5 | 151.8 | 25% | 194.8 | -3% | 384.3 | 279.0 | 38% |
| OPERATING INCOME (EXPENSES) | -337.2 | -126.3 | 167% | -139.4 | 142% | -476.5 | -247.9 | 92% |
| General and administrative expenses | -335.5 | -126.8 | 165% | -139.6 | 140% | -475.1 | -242.5 | 96% |
| Other operating income (expenses), net | -1.6 | 0.5 | -435% | 0.2 | -906% | -1.4 | -5.5 | -74% |
| Equity accounting result | 0.,0 | 0.0 | | 0.0 | | 0.0 | 0.0 | |
| OPERATING INCOME (LOSS) BEFORE FINANCIAL RESULTS | -147.7 | 25.5 | -679% | 55.4 | -367% | -92.3 | 31.1 | -397% |
| FINANCIAL OUTCOME | -36.1 | -15.1 | 139% | -27.7 | 31% | -63.8 | -29.6 | 115% |
| Financial Revenues | 8.4 | 3.3 | 156% | 9.8 | -14% | 18.2 | 7.3 | 149% |
| Financial Expenses | -44.6 | -18.4 | 142% | -37.5 | 19% | -82.0 | -37.0 | 122% |
| OPERATING INCOME (LOSS) BEFORE INCOME TAX AND SOCIAL CONTRIBUTION | -183.8 | 10.4 | -1872% | 27.7 | -762% | -156.0 | 1.5 | -10665% |
| INCOME TAX AND SOCIAL CONTRIBUTION | -18.7 | -14.0 | 34% | -21.2 | -11% | -39.9 | -25.5 | 56% |
| Current | -17.6 | -17.1 | 3% | -25.6 | -31% | -43.1 | -34.4 | 26% |
| Deferred | -1.2 | 3.1 | -138% | 4.4 | -127% | 3.3 | 8.8 | -63% |
| NET INCOME (LOSS) FOR THE PERIOD | -202.5 | -3.7 | 5447% | 6.6 | -3172% | -195.9 | -24.0 | 715% |

Recent Events

➤ CAM/Clion Group Acquisition

On April 17, 2021, an Agreement for the Purchase and Sale of Quotas and Other Covenants was signed with the CAM Companies, which develop activities of medical-hospital services and diagnostic medicine, mainly related to oncology and hematology, also including in its portfolio services of bone densitometry, nuclear medicine, procedures of care, diagnosis, therapy, and performance of complementary exams, diagnostic imaging and magnetic resonance, among others, and are located in the city of Salvador, in the state of Bahia.

The acquisition price for all the quotas issued by CAM Companies agreed between the parties is R\$313.2 million, subject to adjustments.

The closing of the transaction is subject to the usual conditions precedent for this type of transaction, including approval by CADE, which have not yet been concluded.

➤ Acquisition of Hospital UMC

On July 06, 2021, the Agreement for the Purchase and Sale of Shares and Other Covenants ("CCV") was signed, through which Multihemo Serviços Médicos S.A. ("Buyer"), a subsidiary of the Company, undertook to acquire shares representing 84% of the capital of Complexo Hospitalar Uberlândia S.A. ("UMC"), with the provision for an additional investment by the Buyer, through subscription and payment of a capital increase of UMC, in case two other companies (UMC Imagem Ltda. and Instituto do Coração do Triângulo Mineiro Ltda.) are acquired by UMC before the closing of the transaction ("Additional Investment").

The acquisition price for the shares issued by UMC mentioned above is R\$ 242,159,245.12, subject to adjustments, and may be increased by up to R\$ 51,751,226.00, subject to adjustments, upon the occurrence of the Additional Investment. The closing of the transaction is subject to the usual conditions precedent for this type of transaction, including CADE's approval, which have not yet been concluded.

Recent Events (Continued)

➤ Acquisition of CEBROM Group

On May 27, 2021, the Agreement for the Purchase and Sale of Quotas and Other Covenants was signed, whereby Oncoclínica - Centro de Tratamento Oncológico S.A, a subsidiary of the Company, undertook to acquire quotas representing (i) 100% of the capital stock of the

capital of the Brazilian Center of Radiotherapy Oncology and Mastology CEBROM Ltda. ("CEBROM"), (ii) up to 63.70% of the capital stock of CTR Centro de Tratamento Radioterápico Ltda. ("CTR Bueno"), and (iii) up to 68.20% of the capital stock of CTR Centro de Tratamento Radioterápico de Anápolis ("CTR Anápolis" and, together with CEBROM and CTR Bueno, the "Companies").

The acquisition price for all the shares issued by the Companies agreed between the parties is R\$232,486,742.97, subject to adjustments. The closing of the transaction is subject to the usual conditions precedent for this type of transaction, including approval by CADE, which have not yet been concluded.

➤ Partnership with Unimed Grande Florianópolis

On February 17, 2021, a strategic partnership agreement was signed with Unimed Grande Florianópolis ("UGF"), to jointly serve the beneficiaries of the health plans offered by the UGF, in addition to patients served through exchange with the Unimed National System and patients from other health plans, who, in accordance with international disease codes, and who seek oncology services through the company, guaranteeing, as a priority, the referral of patients who are beneficiaries of the UGF's health plans.

Recent Events (Continued)

➤ Initial Public Offering (IPO)

Oncoclínicas Group started trading its shares ("ONCO3" on B3) on August 10, 2021, after an Initial Public Offering (IPO), which moved R\$2.7 billion, including the issuance of 90,049,527 new shares that injected R\$1.7 billion in the Company's cash. The Oncoclínicas Group joined the Novo Mercado listing segment, in line with its continuous search for the highest standards of corporate governance. The use of the funds raised in the operation will be mostly used to support the company's growth, either in M&A operations (75% of the use of the offer's funds) or in organic growth (25% of the use of the offer's funds).

➤ Share Buyback

On July 7, 2021, the Company's shareholders approved the repurchase, by the Company, of 28,371,574 common shares issued by the Company, pro rata to all its shareholders on that date ("Share Buyback"), by amount of R\$1.00232132 per share, equivalent to the book value of the shares on the base date of March 31, 2021, considering the Company's share split approved at the Company's General Shareholders' Meeting held on May 26, 2021, and through the use of resources available in the capital reserve existing on the date of the EGM, to be held in treasury.

Recent Events (Continued)

➤ Acquisition of minority interest

- **Multihemo S.A. (Recife)** - Purchase of 25.63% minority stake on the condition of (i) a cash installment fixed at R\$ 27.6 million, settled on the closing date; (ii) a variable future installment, being assured the payment of the minimum amount of R\$ 39.05 million; and (iii) up to 11 semi-annual variable future installments. With this acquisition, Oncoclínicas guarantees a 100% stake in the unit.
- **Radioterapia Oncoclínicas Recife S.A.** – Purchase of a 2.40% minority stake with a single lump sum payment of R\$ 132 thousand, paid on the closing date. With this acquisition, Oncoclínicas guarantees a 100% stake in the unit.
- **CPO – Centro Paraibano de Oncologia S.A. (João Pessoa)** – Purchase of 25% minority stake on the condition of payment of (i) a fixed cash installment of R\$ 9.8 million, settled on the closing date; (ii) a variable future installment, being assured the payment of the minimum amount of R\$ 14.8 million; and (iii) up to 11 semi-annual variable future installments. With this acquisition, Oncoclínicas guarantees a 100% stake in the unit.
- **NOS – Núcleo de Oncologia de Sergipe S.A. (Aracaju)** – Purchase of 56.79% minority stake on the condition of payment of (i) a fixed cash installment of R\$ 21.5 million, settled on the closing date; (ii) a variable future installment, being assured the payment of a minimum amount of R\$ 13.1 million; and (iii) up to 11 semi-annual variable future installments. With this acquisition, Oncoclínicas guarantees a 100% stake in the unit.

Recent Events (Continued)

➤ Acquisition of minority interest (Continued)

- **Hematológica – Clínica de Hematologia S.A. (Belo Horizonte)** – Purchase of 41.98% minority stake on the condition of payment of (i) a fixed cash installment of R\$ 14.8 million, settled on the closing date; (ii) a variable future installment, being assured the payment of a minimum amount of R\$ 20.1 million; and (iii) up to 11 semi-annual variable future installments. With this acquisition, Oncoclínicas guarantees a 100% stake in the unit.
- **Instituto de Hematologia e Oncologia de Curitiba – Clínica Médica S.A. -** Purchase of 6% of the minority stake on the condition of payment of a single lump sum of R\$ 4.3 million, paid on the closing date. With this acquisition, Oncoclínicas guarantees a 72% stake in IHOC's capital stock.
- **CECON – Centro Capixaba de Oncologia S.A. (Vitória)** – Purchase of 13.5% of the minority stake on condition of payment of a single lump sum of R\$ 6.8 million, settled on the closing date. With this acquisition, Oncoclínicas guarantees an 81.5% stake in CECON's capital stock.
- **Aliança Instituto de Oncologia S.A. (Brasília)** – Purchase of 25% of the minority stake on condition of payment of a single lump sum of R\$ 40.2 million, settled on the closing date. With this acquisition, Oncoclínicas guarantees an 80% stake in Aliança's capital stock.
- **OncoVida Instituto Especializado de Oncologia Clínica S.A. (Brasília)** – Purchase of 24.04% minority stake in a single lump sum payment of R\$ 13.9 million, settled on the closing date. With this acquisition, Oncoclínicas guarantees 84.04% of participation in OncoVida's capital stock.

